Andrew Reardon's most recent trade in Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B was a trade of 500 Common Stock done at an average price of $114.1 . Disclosure was reported to the exchange on June 23, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Ligand Pharmaceuticals, In... | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 114.08 per share. | 23 Jun 2025 | 500 | 31,903 (0%) | 0% | 114.1 | 57,042 | Common Stock |
| Ligand Pharmaceuticals, In... | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 114.54 per share. | 10 Jun 2025 | 500 | 32,403 (0%) | 0% | 114.5 | 57,271 | Common Stock |
| Ligand Pharmaceuticals, In... | Andrew Reardon | CLO & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 28,043 | 28,043 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Andrew Reardon | CLO & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 6,415 | 34,783 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | Andrew Reardon | CLO & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 6,928 | 29,462 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | Andrew Reardon | CLO & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 5,429 | 32,116 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | Andrew Reardon | CLO & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 120.00 per share. | 14 Feb 2025 | 2,775 | 26,687 (0%) | 0% | 120 | 333,000 | Common Stock |
| Ligand Pharmaceuticals, In... | Andrew Reardon | CLO & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 120.00 per share. | 14 Feb 2025 | 1,758 | 30,358 (0%) | 0% | 120 | 210,960 | Common Stock |
| Ligand Pharmaceuticals, In... | Andrew Reardon | CLO & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 120.00 per share. | 14 Feb 2025 | 1,114 | 29,244 (0%) | 0% | 120 | 133,680 | Common Stock |
| Ligand Pharmaceuticals, In... | Andrew Reardon | CLO & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 120.00 per share. | 14 Feb 2025 | 876 | 28,368 (0%) | 0% | 120 | 105,120 | Common Stock |
| Ligand Pharmaceuticals, In... | Andrew Reardon | CLO & Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Sep 2024 | 2,000 | 70,944 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 99.60 per share. | 23 Sep 2024 | 2,000 | 22,534 (0%) | 0% | 99.6 | 199,201 | Common Stock |
| Ligand Pharmaceuticals, In... | Andrew Reardon | CLO & Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 52.27 per share. | 23 Sep 2024 | 2,000 | 24,534 (0%) | 0% | 52.3 | 104,540 | Common Stock |
| Ligand Pharmaceuticals, In... | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 106.39 per share. | 28 Aug 2024 | 1,500 | 22,534 (0%) | 0% | 106.4 | 159,591 | Common Stock |
| Ligand Pharmaceuticals, In... | Andrew Reardon | CLO & Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Aug 2024 | 1,500 | 61,444 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Andrew Reardon | CLO & Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 52.27 per share. | 28 Aug 2024 | 1,500 | 24,034 (0%) | 0% | 52.3 | 78,405 | Common Stock |
| Ligand Pharmaceuticals, In... | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 104.00 per share. | 10 Aug 2024 | 1,000 | 32,903 (0%) | 0% | 104 | 104,000 | Common Stock |
| Ligand Pharmaceuticals, In... | Andrew Reardon | CLO & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 100.15 per share. | 10 Aug 2024 | 897 | 21,637 (0%) | 0% | 100.2 | 89,839 | Common Stock |
| Ligand Pharmaceuticals, In... | Andrew Reardon | Chief Legal Officer & | Other type of transaction at price $ 60.71 per share. | 28 Jun 2024 | 329 | 22,534 (0%) | 0% | 60.7 | 19,973 | Common Stock |
| Ligand Pharmaceuticals, In... | Andrew Reardon | Chief Legal Officer & | Exercise or conversion of derivative security received from the company (such as an option) at price $ 52.27 per share. | 09 May 2024 | 10,000 | 32,205 (0%) | 0% | 52.3 | 522,700 | Common Stock |
| Ligand Pharmaceuticals, In... | Andrew Reardon | Chief Legal Officer & | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 May 2024 | 10,000 | 62,944 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Andrew Reardon | Chief Legal Officer & | Sale of securities on an exchange or to another person at price $ 83.04 per share. | 09 May 2024 | 10,000 | 22,205 (0%) | 0% | 83.0 | 830,449 | Common Stock |
| Ligand Pharmaceuticals, In... | Andrew Reardon | CHIEF LEGAL OFFICER & | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 29,272 | 29,272 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Andrew Reardon | CHIEF LEGAL OFFICER & | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 7,208 | 22,205 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | Reardon Andrew | CHIEF LEGAL OFFICER & | Payment of exercise price or tax liability using portion of securities received from the company at price $ 74.65 per share. | 15 Feb 2024 | 593 | 14,997 (0%) | 0% | 74.6 | 44,267 | Common Stock |
| Ligand Pharmaceuticals, In... | Reardon Andrew | CHIEF LEGAL OFFICER & | Other type of transaction at price $ 60.71 per share. | 29 Dec 2023 | 179 | 15,590 (0%) | 0% | 60.7 | 10,867 | Common Stock |
| Ligand Pharmaceuticals, In... | Andrew Reardon | CHIEF LEGAL OFFICER & | Payment of exercise price or tax liability using portion of securities received from the company at price $ 68.73 per share. | 10 Aug 2023 | 897 | 15,411 (0%) | 0% | 68.7 | 61,651 | Common Stock |
| Ligand Pharmaceuticals, In... | Andrew Reardon | See Remarks | Sale of securities on an exchange or to another person at price $ 69.92 per share. | 24 Mar 2023 | 300 | 16,308 (0%) | 0% | 69.9 | 20,977 | Common Stock |
| Ligand Pharmaceuticals, In... | Andrew Reardon | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 15,393 | 15,393 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Andrew Reardon | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 5,668 | 16,608 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | Andrew Reardon | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 72.90 per share. | 30 Nov 2022 | 1,073 | 10,940 (0%) | 0% | 72.9 | 78,222 | Common Stock |